|
|
Post by alethea on Sept 22, 2017 11:49:27 GMT -5
Hmmmm. Best scripts ever since the Sanofi break and zero volume and static price. Cheaters laying in the weeds?
I wonder if the Manipulators are laying low today for the moment. I'm wondering/hoping? that maybe we'll see BIG volume late today and a significant/big jump in PPS near the end of the day.
A body can hope.
|
|
|
|
Post by straightly on Sept 22, 2017 13:58:32 GMT -5
Hmmmm. Best scripts ever since the Sanofi break and zero volume and static price. Cheaters laying in the weeds? I wonder if the Manipulators are laying low today for the moment. I'm wondering/hoping? that maybe we'll see BIG volume late today and a significant/big jump in PPS near the end of the day. A body can hope. Scratching my head. Bought a few more. Already under water a little. Feeling comfortable. |
|
|
|
Post by celo on Sept 22, 2017 14:03:14 GMT -5
Stock sure likes that old 40/cents a share level. I think the previous run up was someone taking a sizable position. Mannkind sales keep increasing as they do...time is on our side.
|
|
|
|
Post by kite on Sept 22, 2017 14:46:15 GMT -5
Hmmmm. Best scripts ever since the Sanofi break and zero volume and static price. Cheaters laying in the weeds? I wonder if the Manipulators are laying low today for the moment. I'm wondering/hoping? that maybe we'll see BIG volume late today and a significant/big jump in PPS near the end of the day. A body can hope. Scratching my head. Bought a few more. Already under water a little. Feeling comfortable. We're in the same boat, straightly! I just bought a few more too after testing my patience with this decline. |
|
|
|
Post by boytroy88 on Sept 22, 2017 14:59:16 GMT -5
The funny thing I've been noticing is that every time the pps goes up with a decent sized amount of shares it gets driven down by a 100 share bid...crazy.
|
|
|
|
Post by falconquest on Sept 22, 2017 15:36:08 GMT -5
Stock sure likes that old 40/cents a share level. I think the previous run up was someone taking a sizable position. Mannkind sales keep increasing as they do...time is on our side. Time is on our side? How do you come to that conclusion? |
|
|
|
Post by celo on Sept 22, 2017 17:20:28 GMT -5
Stock sure likes that old 40/cents a share level. I think the previous run up was someone taking a sizable position. Mannkind sales keep increasing as they do...time is on our side. Time is on our side? How do you come to that conclusion? Well... The CEO has been very upfront and has not seemed to lie or really overinflated expectations, yet. So I'm sticking with him when he says, "We have a lot of options when it comes to finances" I'm sticking with him, when he says, sales will be 8 to 14 million in the second half of 2017 and will continue to grow in 2018. I'm sticking with him when he says that the label will change for the better soon and we will have better contracts with insurances when that happens. So he keeps acting like Mannkind will be around for a while and he doesn't seem like some other CEOs that give promises that won't occur. So I say time is on our side. One other note, I have not studied a lot of biopharma companies but ones that exhibit 30% week over week growth I would assume won't go bankrupt anytime soon. But maybe they do. |
|
|
|
Post by mnkdorbust on Sept 22, 2017 17:37:00 GMT -5
The funny thing I've been noticing is that every time the pps goes up with a decent sized amount of shares it gets driven down by a 100 share bid...crazy. I bought an additional 4000 shares yesterday and most of them came in 100 share increments on a single placed order. |
|
|
|
Post by sportsrancho on Sept 22, 2017 17:57:59 GMT -5
stockinvest.us/technical-analysis/MNKDMannKind Corporation lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 58.9% during the next 3 months and, with 90% probability hold a price between $2.53 and $3.75 at the end of this period.
|
|
|
|
Post by falconquest on Sept 23, 2017 8:07:13 GMT -5
Time is on our side? How do you come to that conclusion? Well... The CEO has been very upfront and has not seemed to lie or really overinflated expectations, yet. So I'm sticking with him when he says, "We have a lot of options when it comes to finances" I'm sticking with him, when he says, sales will be 8 to 14 million in the second half of 2017 and will continue to grow in 2018. I'm sticking with him when he says that the label will change for the better soon and we will have better contracts with insurances when that happens. So he keeps acting like Mannkind will be around for a while and he doesn't seem like some other CEOs that give promises that won't occur. So I say time is on our side. One other note, I have not studied a lot of biopharma companies but ones that exhibit 30% week over week growth I would assume won't go bankrupt anytime soon. But maybe they do. And my thesis is that while there are lots of potential positive developments that may occur soon the unfortunate fact is we're running out of money and damned soon. Scripts could rise by multitudes but Mannkind are still a long way from break even let alone making an actual profit. So Mike says they have many options for financing, care to let us know what you believe are good options that will carry us more than a month or two? |
|
|
|
Post by dreamboatcruise on Sept 24, 2017 0:25:10 GMT -5
Time is on our side? How do you come to that conclusion? Well... The CEO has been very upfront and has not seemed to lie or really overinflated expectations, yet. So I'm sticking with him when he says, "We have a lot of options when it comes to finances" I'm sticking with him, when he says, sales will be 8 to 14 million in the second half of 2017 and will continue to grow in 2018. I'm sticking with him when he says that the label will change for the better soon and we will have better contracts with insurances when that happens.So he keeps acting like Mannkind will be around for a while and he doesn't seem like some other CEOs that give promises that won't occur. So I say time is on our side. One other note, I have not studied a lot of biopharma companies but ones that exhibit 30% week over week growth I would assume won't go bankrupt anytime soon. But maybe they do. Has he really said the label change will happen, or merely stated what they are trying to get and when the decision will be made by FDA? Those obviously are different things. You may be hearing "promises" that have not really been made. |
|
|
|
Post by dreamboatcruise on Sept 24, 2017 0:28:22 GMT -5
Well... The CEO has been very upfront and has not seemed to lie or really overinflated expectations, yet. So I'm sticking with him when he says, "We have a lot of options when it comes to finances" I'm sticking with him, when he says, sales will be 8 to 14 million in the second half of 2017 and will continue to grow in 2018. I'm sticking with him when he says that the label will change for the better soon and we will have better contracts with insurances when that happens.So he keeps acting like Mannkind will be around for a while and he doesn't seem like some other CEOs that give promises that won't occur. So I say time is on our side. One other note, I have not studied a lot of biopharma companies but ones that exhibit 30% week over week growth I would assume won't go bankrupt anytime soon. But maybe they do. Has he really said the label change will happen, or merely stated what they are trying to get and when the decision will be made by FDA? Those obviously are different things. You may be hearing "promises" that have not really been made. You do know we're not nearly coming close to average 30% week over week growth, right? That doesn't require studying other biopharmas, just being realistic about the one we're invested in. All sorts of wrong assumptions can be made when one picks single data points and ignore the vast majority of the data. |
|
|
|
Volume too
Sept 24, 2017 7:33:17 GMT -5
via mobile
Post by cjm18 on Sept 24, 2017 7:33:17 GMT -5
Looks like they are Waiting for the label change to dilute. The perfect trade would be buy dips now and sell the label change news. The lack of volume on Friday after scripts came out is telling as was the 75% short interest.
|
|
|
|
Post by thekid2499 on Sept 24, 2017 8:15:55 GMT -5
$100 million is what we need to give me comfort. If we can get 5% script growth (week over week), we will start being profitable by the end of next year. I realize that our loss every month will be mitigated as scripts grow, but I think $100 million will completely release the pressure from shorts and give the street confidence in MNKD. Can we get our hands on $100 million without dilution? I don't know. I would be all for selling exclusive rights to Technosphere for a drug or two if that is what it takes to get us there.
|
|
|
|
Post by lennymnkd on Sept 24, 2017 8:26:54 GMT -5
Will the study , LAKERS posted / 60 patents ... four weeks , time in range , CGM to be completed on OCT 15 have any effect on label delay : on or before sept 29th ?
|
|
